[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554844":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":19,"id":55,"slug":19,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":19,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCR-PDL1","EXPERIMENTAL","Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.",[13],"Drug: DCR-PDL1",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Solution for IV Infusion",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[31,44],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":19},"NEXT Oncology","RECRUITING","Irving","Texas","75039","United States",{"type":39,"coordinates":40},"Point",[41,42],-96.94889,32.81402,{"lat":42,"lon":41},{"facility":45,"status":33,"city":46,"state":35,"zip":47,"country":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":19},"Next Oncology","San Antonio","78229",{"type":39,"coordinates":49},[50,51],-98.49363,29.42412,{"lat":51,"lon":50},{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100554844",false,"NCT06504368","Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors","An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors","Inclusion Criteria:\n\n* Male or female adults, aged greater than or equal to (≥) 18 years.\n* Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma\n\n  * that is refractory to standard therapy known to provide clinical benefit for their condition OR\n  * have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR\n  * have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR\n  * for which no standard therapy is available\n* Measurable disease according to RECIST version 1.1.\n* Malignancy not currently amenable to surgical intervention.\n* ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent.\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.\n* Other protocol defined exclusion criteria could apply","ALL","18 Years",{"count":64,"type":65},32,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.",[71],"Solid Tumors, Adult","2025-11-04",{"date":74,"type":75},"2025-11-06","ACTUAL",{"date":77,"type":75},"2024-05-29",{"date":79,"type":65},"2027-12-31",{"name":81,"class":6},"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",2]